Malignant minor salivary gland tumors: A retrospective study of 28 cases: Clinical experience of a single institution by Anter, Abeer Hussien & Hamed, Rasha Hamdy
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Corresponding author: Abeer Hussien Anter; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt.
Cite this article as: Anter AH, Hamed RH. Malignant minor salivary gland tumors: A retrospective study of 28 cases: Clinical experience of a single institu-
tion. Int J Cancer Ther Oncol 2015; 3(1):030114. DOI:10.14319/ijcto.0301.14
© Anter et al. ISSN 2330-4049
Malignant minor salivary gland tumors: A retrospective study of
28 cases: Clinical experience of a single institution
Abeer Hussien Anter, Rash Hamdy Hamed
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt
Received October 29, 2014; Revised December 21, 2014; Accepted December 29, 2014; Published Online January 01, 2015
Original Article
Abstract
Purpose: This retrospective study was done to report our experience with the management of patients with primary malignant
tumors of minor salivary glands that were treated with various combinations of surgery, radiation, and chemotherapy and to
review treatment outcome. Methods: The records of all patients with malignant minor salivary gland tumors presenting for
treatment at our department between 2000 and 2010 were retrospectively reviewed. Variables were collected and outcome
measures were defined in terms of overall survival, disease-free survival. Descriptive statistics were compiled and statistically
evaluated. Survival was described using the Kaplan-Meier method. Results: Twenty eight patients (10 males and 18 females)
ranging in age from 18 to 80 years (median, 64 years) met the criteria for inclusion in the study. The majority of tumors were
located in the oral cavity (n = 20), followed by nasal cavity and paranasal sinuses (n = 8). Adenoid cystic carcinoma was the most
common neoplasm (n = 18). All patients were treated with surgery as the primary modality. Neck dissection was performed in
18% of patients, and all patients (n = 28) were treated with adjuvant external beam radiation therapy to a dose of 50 to 60 Gy.
The disease-free survival rate and overall survival at 5 years were 80% and 85%, respectively. Conclusion: Postoperative radia-
tion therapy is effective in preventing local recurrence in most patients with minor salivary gland tumors after gross total exci-
sion.
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Introduction
Minor salivary glands (MSG) are numerous (700 to 900) exo-
crine glands, which are distributed in the submucosa of the
oral cavity, nasopharynx, tonsils, hypopharynx, and larynx.
Heterotopic sites include lymph nodes, the thyroid gland,
facial bones, and the hypophysis.1-3Tumors of the intra-oral
minor salivary glands constitute 2-3% of all malignant neo-
plasms of the upper aero digestive tract and less than 25% of
all salivary gland tumors.2 Tumors arising at major salivary
glands due to their well-defined anatomic borders and their
higher incidence cannot be directly compared to minor sali-
vary gland tumors. Most tumors arising at minor salivary
glands are malignant.4, 5
Surgery is the accepted primary modality of treatment for
most of these tumors.6 The role of radiation in the
post-surgical setting is less clear because there are few large
series with long follow-up. Thus, the treatment approach to
minor salivary gland tumors is based on principles of treat-
ment of major salivary gland tumors, where a larger experi-
ence with postoperative radiation has established its value in
patients with locally advanced disease; recurrent disease in
an unirradiated site; high grade histological type; perineural
spread; close, uncertain, or positive surgical margins; or neck
nodal disease.7
These features are relatively more common in minor salivary
gland tumors because they have a higher incidence of ma-
lignancy than do parotid tumors, adenoid cystic carcinomas
are more common, and it is frequently harder to get clear
margins, particularly in tumors arising from the paranasal
sinuses. Thus, it is reasonable to expect that postoperative
radiation would have a correspondingly greater role in their
management.8Malignant tumors of minor salivary glands are
very rare. Therefore, design of management protocols is
challenging. So our study that reports our experience in
management of malignant MSG tumors beside other retro-
spective studies may help to design a protocol of manage-
ment for those patients.
This study aims to retrospectively review our experience
with the management of patients with primary malignant
tumors of minor salivary glands that were treated with vari-
ous combinations of surgery, radiation, and chemotherapy
and to review treatment outcome, over ten years within a
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single radiotherapy (RT) unit in a large tertiary referral cen-
tre in our locality.
Methods and Materials
This study is a retrospective study of patients with primary
malignant tumors of MSG that has been treated by
post-operative radiotherapy at Clinical Oncology & Nuclear
Medicine Department, Mansoura University Hospital during
the 10-year period (2000 to 2010).
A total 38 patients with primary malignant tumors of minor
salivary gland were identified. The medical records of all
patients with primary malignant tumors of MSG, were retri-
eved and reviewed. Demographic data, clinical characteris-
tics, diagnostic investigations, histological typing, treatment
modalities including type of surgery, radiotherapy and che-
motherapy, follow-up, recurrence, and survival were noted.
All patients provided a history and underwent physical ex-
amination. Radiologic imaging included chest x-ray, and
computed tomography or magnetic resonance imaging scans.
Computed tomography was preferred for cases with bone
involvement, whereas MRI was reserved solely for soft tissue
invasion.
Radiotherapy
All patients received their radiation therapy with or without
cisplatin after a surgical procedure for removing a primary
minor salivary gland cancer or after surgery for locally re-
current disease.
FIG. 1: A 58 year-old man with T4N0M0 Adenoid cystic carcinoma
of Rt maxillary sinus, for post-operative radiotherapy to tumor bed
only (nodal regions not electively treated). (a) Axial. (b) Sagittal
images displaying isodose distributions. Shaded blue is PTV.
The interval between the date of last surgery and start of
radiation therapy ranged from 2 to 8 weeks. Radiation tech-
niques were dependent on the primary site. The techniques
were grouped as follows: single appositional fields, parallel
opposed fields, three field techniques, and wedged paired
fields (Figure 1), with megavoltage equipment, using co-
balt-60 gamma rays, 6 MeV linear accelerator or 6-20 MeV
electrons. Doses to the primary sites ranged from 5000 to
6000 cGy. The median number of fractions per course of
treatment was 30. Concurrent chemotherapy consisted of
cisplatin, which was typically administered weekly with a
dose of 40 mg/m2.
Statistical analysis
The Kaplan-Meier method was used to estimate survival.
Overall survival was defined as the interval between diagno-
sis and death or last follow-up. Disease-free survival (DFS)
was defined as the interval between from the date of surgery
to the earliest time of recurrence in local or distant sites,
death from any cause or last follow-up.
A p-value ≤0.05 was considered significant. All analyses were
conducted with SPSS version 15.0 (SPSS for Windows, Rel.
13.0 2004. Chicago: SPSS Inc.).
Results
In the 10-year period of 2000 to 2010, 38 patients with mi-
nor salivary gland malignancy were treated in our institu-
tion, Patients with unresected or gross residual disease after
attempted resection (6 patients) or with distant metastatic
disease at the time of their radiation (4 patients) were ex-
cluded from the study. This left 28 patients between the ages
of 18 and 75 years (median, 64 years) for inclusion in this
analysis. Eighteen patients were female, and 10 were male.
The primary tumor site was in the oral cavity in 20 patients
and in nasal cavity or paranasal sinuses in 8 patients (Table
1). The chief complaint on presentation was a lump (60%),
followed by an ulcerated lump (22%). Overall 82% of the
patients presented a lump with or without ulceration of the
surface.
TABLE 1: Primary Site in 28 Patients With malignant minor sali-
vary gland tumors.








Floor of mouth 4
Gingiva/alveolar ridge 2
Retromolar trigone 2
Most patients (18) had a histologic diagnosis of adenoid cyst-
ic carcinoma. 6 mucoepedermoid carcinoma and 4 patients
had adenocarcinoma (Table 2). Surgical procedures varied
dependent on the size and site of the primary lesion. 2 pa-
tients had excisional biopsies, 14 patients had wide local
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excisions, and the remaining 12 patients had more extensive
resections, including 3partial or total maxillectomies. After
these procedures, 11 (39%) patients had pathologic evidence
of microscopic positive margins, and an additional 6 (21%)
had close (less than 5 mm) or uncertain margins. A neck
dissection was performed on 5 (18%) patients, with patho-
logically positive lymph nodes being found in 3 patients.
Thirteen patients (46.6%) had pathological evidence of
perineural invasion. Bone invasion by the primary was pre-
sent in 6 (21%) patients.





All patients received their radiation therapy with or without
cisplatin after a surgical procedure for removing a primary
minor salivary gland cancer. In 25 patients, radiation therapy
followed the initial surgery; the remaining 3 (10.7%) were
irradiated after surgery for locally recurrent disease.
Local recurrence was recorded in two patients; one after 24
months, other after 5 years. Lung metastasis was only ob-
served in three cases; one of them developed late lung me-
tastasis after 5 years, as confirmed by biopsy from lung le-
sion. Also, three patients developed wide spread metastasis.
Overall, 20 patients were free of local or disseminated dis-
ease at the last follow-up. Seven patients died during the
course of our study. Two patients died due to unrelated
causes (pneumonia, pulmonary embolism), three of them
due to disseminated metastasis and the last two patients due
to respiratory failure. The 5, l0 years overall survival rates for
the whole series were 85%, 66% (Figure 2). On other hand,
the 5, l0 year disease-free survival was 80%, 64% respective-
ly (Figure 3).
FIG. 2: Survival curve for 28 patients with malignant minor salivary
gland tumors treated with postoperative radiation therapy.
FIG. 3: Disease free survival curve for 28 patients with malignant
minor salivary gland tumors treated with postoperative radiation
therapy
Discussion
This study is a retrospective study of patients with primary
malignant tumors of MSG that has been treated at Clinical
Oncology & Nuclear Medicine Department, Mansoura Uni-
versity Hospital. The present study revealed that primary
malignant tumors of MSG occurred in the old population
(median, 64 years). This was also reported by others.5, 9, 10
Patients were more often female than male in our data, with
a ratio of 1.8:1. Review of the literature shows a female pre-
dilection among the patients with primary malignant tumors
of MSG.5, 11, 12
According to other reports 5, 13, 14, 15, the palate was the most
commonly affected site, and this was also seen in our study.
Moore et al.16 suggests that primary malignant tumors of
MSG usually occurred at the junction of the hard and soft
palates due to concentration of salivary glands in this region.
In this study, adenoid cystic carcinoma was the most com-
mon pathological type of primary malignant tumors of MSG
(64.3%) followed by mucoepidermoid carcinoma (21.4%).
Studies concerning west European population 17-19 reported
adenoid cystic carcinoma as the most common malignancy
but according to other reports 11, 20, 21; mucoepidermoid car-
cinoma was the most common malignant MSGTs.
In the present series, a neck dissection was performed on 5
(18%) patients, with pathologically positive lymph nodes
being found in 3 (10.7%) patients which abides to the gen-
eral proportion of 4 to 10% recorded in other studies 10, 22, 23,
Many factors usually dictate selective neck dissection, such
as the site and size (T) of the tumor, the histological grade,
and the age of the patient. Parsons et al. have classified MSG
4 Anter et al.: Malignant minor salivary gland tumors International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Anter et al. ISSN 2330-4049
tumor sites according to the incidence of node positivity 24,
according to this classification; low incidence (less than 10%)
is observed in MSG tumors of the hard palate, nasal cavity,
paranasal sinuses, lip, and buccal mucosa. The intermediate
risk of positive neck at presentation should be expected in
MSG tumors of the floor of the mouth and tongue. The
higher risk for node metastases lies with MSG tumors of the
pharynx and larynx. However, other authors advocate sig-
nificantly lower lymph node infiltration than hematogenous
metastases for MSG tumors.25
All patients received their radiation therapy after a surgical
procedure for removing a primary minor salivary gland can-
cer. In 25 patients, radiation therapy followed the initial
surgery; the remaining 3 (10.7%) were irradiated after sur-
gery for locally recurrent disease.
Adjuvant radiotherapy was offered to patients who present-
ed with advanced stage, histopathologically proven positive
neck metastases, close or positive margins and perineural
invasion, Combination of radiotherapy and cisplatin was
offered to patients with high grade histological subtype and
advanced stage of the disease at presentation. Other authors
reserve such a therapy for patients with distant metastases 2,
26, 27 or as palliative treatment.21, 25
In this study, The 5 year survival rates for the whole series
were 89% and this was also seen in another study.3, 11 This
trial has some limitations. One is the relatively small number
of patients another factor is that it is a single institution
study. Multicenter randomized Trials are necessary to clarify
the role of radiotherapy in patients with MSG tumors.
Conclusion
Patients with minor salivary gland malignancies considered
at high risk of local failure benefit from postoperative radia-
tion. Local control rates are comparable to those reported for
major salivary gland tumors, also late recurrences and me-
tastases that were also noted in our study conﬁrm the neces-
sity of long-term follow-up of these patients, more than 5
years.
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